Hepalink will exit the immune and inflammatory disease drug developer in an acquisition that could reach $1.45bn in size.
Pharmaceutical firm Sanofi agreed yesterday to acquire UK-based monoclonal antibody therapy developer Kymab in a deal sized at up to $1.45bn that will enable pharmaceutical manufacturer Shenzhen Hepalink to exit.
The transaction will consist of $1.1bn in cash and up to $350m in milestone payments. It comes after approximately $220m in funding for the company.
Founded in 2010, Kymab is developing treatments for cancer and immune-mediated diseases. Its lead product candidate, KY1005, is a monoclonal antibody that could potentially treat…
